PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-142.73%
Both yoy net incomes decline, with CRVO at -7.05%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
55.79%
Some D&A expansion while CRVO is negative at -4.68%. John Neff would see competitor’s short-term profit advantage unless expansions here deliver big returns.
71.34%
Deferred tax of 71.34% while CRVO is zero at 0.00%. Bruce Berkowitz would see a partial difference that can matter for future cash flow if large in magnitude.
-22.08%
Negative yoy SBC while CRVO is 42.64%. Joel Greenblatt would see less immediate dilution advantage if talent levels remain strong.
83.34%
Well above CRVO's 5.44% if positive yoy. Michael Burry would see a risk of bigger working capital demands vs. competitor, harming free cash flow.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
76.76%
AP growth well above CRVO's 22.00%. Michael Burry would be concerned about potential late payments or short-term liquidity strain relative to competitor.
-41.25%
Both reduce yoy usage, with CRVO at -142.85%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
-22.08%
Both negative yoy, with CRVO at -37.90%. Martin Whitman would suspect an overall environment of intangible cleanup or shifting revaluations for the niche.
9.39%
Some CFO growth while CRVO is negative at -6.40%. John Neff would note a short-term liquidity lead over the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-3.94%
We cut debt repayment yoy while CRVO is 0.00%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
-35.14%
Negative yoy issuance while CRVO is 0.00%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.